Simulations Plus (NASDAQ:SLP) Posts Earnings Results, Beats Expectations By $0.02 EPS

Simulations Plus (NASDAQ:SLP - Get Free Report) posted its quarterly earnings data on Wednesday. The technology company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02, Briefing.com reports. The company had revenue of $18.70 million during the quarter, compared to analysts' expectations of $19.73 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. Simulations Plus's revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period in the prior year, the business earned $0.18 earnings per share. Simulations Plus updated its FY25 guidance to $1.07 to $1.20 EPS and its FY 2025 guidance to 1.070-1.200 EPS.

Simulations Plus Stock Performance

Simulations Plus stock traded down $0.28 during trading hours on Friday, hitting $30.68. 276,597 shares of the stock were exchanged, compared to its average volume of 130,076. Simulations Plus has a 12 month low of $29.37 and a 12 month high of $51.22. The business's 50-day moving average is $33.08 and its two-hundred day moving average is $40.63. The stock has a market capitalization of $613.91 million, a P/E ratio of 63.92 and a beta of 0.69.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Craig Hallum reiterated a "buy" rating and issued a $56.00 price objective on shares of Simulations Plus in a research report on Wednesday, July 3rd. William Blair reaffirmed an "outperform" rating on shares of Simulations Plus in a research report on Thursday. JMP Securities started coverage on shares of Simulations Plus in a report on Tuesday, July 16th. They issued a "market perform" rating on the stock. BTIG Research reduced their price objective on shares of Simulations Plus from $60.00 to $50.00 and set a "buy" rating for the company in a report on Thursday. Finally, KeyCorp started coverage on shares of Simulations Plus in a research note on Monday, July 29th. They issued an "overweight" rating and a $47.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $54.50.

Insider Transactions at Simulations Plus

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the business's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $31.26, for a total value of $625,200.00. Following the transaction, the director now owns 3,481,592 shares of the company's stock, valued at approximately $108,834,565.92. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 60,750 shares of company stock valued at $2,145,055 in the last three months. 20.90% of the stock is owned by corporate insiders.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.